Eli Lilly has reported new Phase 3b data showing that EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe atopic dermatitis affecting the hands and feet.

The announcement, distributed through PR Newswire, centers on a patient population that dermatologists have long recognized as one of the hardest to treat in atopic dermatitis care. Hand and foot disease carries a disproportionate functional burden: lesions on palmar and plantar skin interfere with work, daily tasks, and quality of life in ways that body-surface-area metrics often understate.

Why the Subset Matters

Atopic dermatitis involving the hands and feet frequently persists even when broader disease activity comes under control. Topical therapies are difficult to apply consistently to acral skin, and the thickened stratum corneum of palmar and plantar surfaces can limit topical penetration. Pain and fissuring, not just itch, drive disability in this cohort. That combination makes dedicated efficacy data for a biologic in this specific population a meaningful addition to the evidence base for clinicians weighing treatment options.

The Agent

Lebrikizumab-lbkz is a monoclonal antibody that inhibits interleukin-13 signaling, a central pathway in atopic dermatitis pathogenesis. Lilly markets it as EBGLYSS. The company's Phase 3b findings, according to the announcement, extend the drug's established profile in moderate-to-severe atopic dermatitis to the hand and foot population, with improvements reported across four domains: skin clearance, itch, pain, and patient satisfaction.

These are the outcomes that matter most in this anatomically defined subset. Itch and pain in hand and foot disease are not interchangeable endpoints — patients with painful fissures may report limited itch relief as insufficient, and patient satisfaction measures capture that functional reality in a way that investigator-scored clearance alone does not.

Reading the Data

The announcement characterizes the improvements as both significant and rapid. For a drug class where onset speed increasingly differentiates agents in a crowded interleukin-targeting market, kinetics of response in highly symptomatic sites such as the hands and feet carry commercial and clinical weight alike.

As with any company-issued release, the figures Lilly highlights — and the trial's precise design, comparator structure, and endpoint definitions — warrant review against the full dataset and any peer-reviewed publication or regulatory submission that follows. The claim structure here, with improvements spanning objective clearance and patient-reported outcomes, points to a multipronged endpoint strategy typical of contemporary Phase 3b programs in atopic dermatitis.

Practice Implications

For clinicians, the data speak to an unmet need at the level of site-specific disease. Patients whose hand and foot involvement dominates their clinical picture have often been managed with therapies extrapolated from trials focused on broader body-surface involvement. Dedicated evidence in this population gives prescribers a firmer basis for selecting a biologic when acral disease is the primary complaint, particularly where pain and functional impairment, rather than visible erythema alone, define the patient's burden.

Patient satisfaction as a reported outcome also aligns with a broader shift in dermatology trial design toward measures that reflect how patients actually function day to day — grip, gait, occupational demands — rather than lesion counts alone.

What Comes Next

Lilly will be expected to present the full Phase 3b results at an upcoming medical congress or in publication, where the dermatology community will look for detailed efficacy figures, safety data in this subset, and durability of response over time.